These findings have demonstrated that OC-STAMP partners CD9 to promote periodontal destruction by upregulation of fusion during osteoclastogenesis, suggesting that anti-OC-STAMP-mAb may lead to the development of a therapeutic regimen for pathological bone destruction such as periodontitis. This evidence concerns the gene TTLL5 and periodontitis.